Is everyone aware of this ? (I'm not a holder, used to be, but...

Is everyone aware of this ? (I'm not a holder, used to be, but thought it would be of interest) ... below is from a mail I received which I believe is public information as I am not a subscriber to Insider Trader, but I get newsletters for free, so this shouldn't be copyright IMO.

[PHARMAXIS (PXS)

Hi Everyone,

As most of you would be aware, we look at buyer demand through our Nielsen Supply Demand Indicator; director buying; and the level of popularity amongst brokers. Well here is a stock that is ticking all of these boxes.

Pharmaxis Ltd, a specialist pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory diseases primarily in Australia, Europe, Korea, and the United States. The company's products include Aridol, a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. It has also developed Bronchitol, a drug designed to hydrate the lungs, restore normal lung clearance, and allows patients to clear mucus; and for the treatment of cystic and pulmonary fibrosis, bronchiectasis, chronic obstructive pulmonary disease, and chronic bronchitis.

We like it for the following reasons:

* Bronchitol has received approval from the Australian Therapeutic Goods Administration (TGA) for marketing in Australia for the treatment of Cystic Fibrosis (CF)

* It is looks like the Bronchitol drug has some significant advantages over exsisting CF drugs

* A director has just bought $100K worth of stock

* This stock is becoming more popular with brokers with a big spike in recommendations this month. 5 analysts currently give it an average strong buy recommendation with a score of 9.5. (Up from a score of 7 last month)

* There is a big spike in buyer demand today (30th November)


more details below....

PHARMAXIS (PXS)

Pharmaxis expects the European Commission to confirm this opinion and grant the Marketing Authorisation for Bronchitol in January 2012.

Pharmaxis CEO Dr Alan Robertson welcomed the decision saying, “This outcome from the CHMP meeting is an important milestone for the company. It is good news for the cystic fibrosis (CF) community which has supported us throughout the development of Bronchitol. As the life expectancy of CF patients has lengthened, the size of the adult population in Europe has increased. Bronchitol will be used for CF patients aged 18 and above, which represents about two thirds of all patients who could potentially benefit from the drug. Pharmaxis will undertake a short term clinical trial in children (age 6-17) with a view to extending the license to this age group.

“Bronchitol is a drug which was discovered and developed in Australia. It is approved for marketing in Australia and is now set to become available throughout the 27 countr ies of the European Union. This outcome represents the culmination of a great deal of work by many people.

“Pharmaxis will move quickly to commercialise Bronchitol in Europe. We have established our supply and logistics arrangements and advanced launch preparations and pricing applications with our marketing partner, Quintiles. The awareness of Bronchitol’s clinical data amongst CF clinicians has increased through publications and presentations at scientific conferences. European clinicians provided valuable support to the CHMP decision and are looking forward to Pharmaxis bringing this new therapeutic treatment option to their patients in the near future.” Dr Robertson said.

Professor Stuart Elborn, President of the European Cystic Fibrosis Society, stated; “Life expectancy in cystic fibrosis is improving but there remains an urgent need for new therapies which can improve lung function and reduce exacerbations. Bronchitol increases mucociliary clearance and w ill be the first approved therapy in Europe with this mechanism of action and has been shown to improve both lung function and reduce exacerbations when added to standard medications in use today. I welcome this decision by the CHMP.”

Robert J. Beall, Ph.D, President and CEO of the American Cystic Fibrosis Foundation said; “The Cystic Fibrosis Foundation is delighted to see an important new CF medicine being made available to patients in Europe. It takes a lot of dedication from industry and the CF community to develop a drug to this point. We are proud to have played a part in this process through our clinical trial group and look forward to Bronchitol being submitted to the FDA early next year.”

Bronchitol’s approval for the treatment of cystic fibrosis patients in Australia and the European Marketing Application are based on the results of two Phase 3 clinical trials involving more than 600 people and conducted in 95 centres throughout the world.


Log into our members area right now and find out more.

http://www.theinsidetrader.com.au/


Happy Trading,
The Inside Trader Team